Clinical Trial Update: Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of Legalon SIL (silibinin) for treatment of hepatitis C recurrence after liver transplantation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Legalon SIL (silibinin)

Snippet

Sponsor: Rottapharm | Conditions: HCV Recurrence After Liver Transplantation | Phase 2 | Status: TERMINATED